Epalinges, Switzerland
Argá Medtech SA is a Swiss-based medical device company that was founded in 2020. The company is focused on redefining cardiac ablation through the development of an innovative non-thermal energy-based system for the treatment of cardiac arrhythmias. Their technology, Coherent Sine-burst electroporation (CSE) and pulsed field ablation (PFA), utilizes Pulsed Electrical Fields (PEF) to create irreversible electroporation of cardiomyocytes, offering a safer, faster, cheaper, and more effective treatment for millions affected by cardiac rhythm disorders and atrial fibrillation.
The company recently secured a significant €54.00M Series B investment on 27 February 2024, with participation from prominent investors including Advent Life Sciences, Earlybird, and Gilde Healthcare.
Argá Medtech's strong leadership team, combined with its pioneering approach to cardiac ablation, positions the company as a compelling player in the manufacturing industry, offering potential for significant advancement and impact in the medical technology field.
